Latest Investments News

IRIS Metals’ Phase II drilling at the Tin Mountain Project confirms exceptional lithium grades and unveils critical minerals like rubidium, positioning the company as a key player in the US critical minerals landscape.

Australian Rare Earths Limited (ASX, AR3) reported strong progress in its Koppamurra Rare Earths Project with high recovery rates and production milestones, while also expanding and resuming drilling at its Overland Uranium Project. The company bolstered its financial position through government grants and option exercises.

Alligator Energy has commenced construction of its pivotal Samphire Field Recovery Trial, marking a significant shift from exploration to development. The company also bolstered its leadership team to support this growth phase and reported promising exploration results at its Big Lake Uranium Project.

Doctor Care Anywhere reports a 7.5% rise in consultations excluding secondary care and sustains positive cashflow for the second consecutive quarter, reaffirming ambitious medium-term growth targets.

Metals X reported a 16.6% decline in tin production at its Renison operation for Q3 2025 due to equipment and processing challenges, while cash reserves rose to $279.5 million. The company continues advancing its Rentails project and maintains strategic investments.

Equatorial Resources reports a postponed arbitration hearing over Congo iron ore disputes and seeks clarity on Guinea permit cancellations, while maintaining a solid cash reserve.

Lindian Resources secures official government confirmation that its Kangankunde Rare Earths Project is exempt from Malawi’s new raw mineral export ban, ensuring uninterrupted progress toward production.

Fitzroy River Corporation reported steady royalty income for the June quarter and highlighted significant progress on several royalty projects, including government approvals for Buru Energy’s Rafael Gas Project and a major equity raise for Endura Mining’s Snowy River Gold development.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Carlton Investments reported a slight rise in net profit and an 8.7% increase in dividends for FY2025, while its investment portfolio grew nearly 60% over five years despite recent market fluctuations.